A Phase II, Open Label, Single Arm, "Proof of Concept" Study of TNFerade Plus Radiation in Patients With Metastatic Melanoma.
Phase of Trial: Phase II
Latest Information Update: 11 May 2011
At a glance
- Drugs Golnerminogene pradenovec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors GenVec
- 26 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2006 New trial record.